Price
Financials
Consolidated, Rs crore| Jun 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Sales | 203 | 245 | 218 |
| Expenses | 145 | 183 | 173 |
| Operating Profit | 58 | 62 | 45 |
| OPM % | 29% | 25% | 21% |
| Other Income | 3 | 0 | 0 |
| Interest | 5 | 7 | 6 |
| Depreciation | 11 | 20 | 22 |
| Profit before tax | 45 | 35 | 18 |
| Tax % | 33% | 22% | 20% |
| Net Profit | 30 | 28 | 14 |
| EPS in Rs | 46.99 | 4.39 | 2.24 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 633 | 682 | 567 | 716 | 752 | 869 |
| Expenses | 438 | 550 | 497 | 544 | 549 | 630 |
| Operating Profit | 195 | 131 | 70 | 172 | 203 | 239 |
| OPM % | 31% | 19% | 12% | 24% | 27% | 27% |
| Other Income | 7 | 3 | 6 | 7 | 4 | -6 |
| Interest | 7 | 3 | 8 | 8 | 17 | 26 |
| Depreciation | 22 | 26 | 29 | 39 | 43 | 53 |
| Profit before tax | 173 | 105 | 39 | 132 | 147 | 153 |
| Tax % | 28% | 27% | 38% | 23% | 34% | 28% |
| Net Profit | 123 | 78 | 23 | 100 | 97 | 110 |
| EPS in Rs | 112.72 | 70.89 | 21.48 | 91.49 | 151.98 | 17.51 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 7% | 15% | 16% | ||
| Compounded Profit Growth | % | -1% | 70% | 19% | ||
| Stock Price CAGR | % | % | % | % | ||
| Return on Equity | % | 12% | 13% | 12% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 13 |
| Reserves | 510 | 588 | 611 | 704 | 804 | 1,137 |
| Borrowings | 47 | 65 | 218 | 247 | 544 | 391 |
| Other Liabilities | 200 | 152 | 151 | 326 | 220 | 240 |
| Total Liabilities | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 |
| Fixed Assets | 261 | 280 | 299 | 448 | 438 | 1,120 |
| CWIP | 28 | 40 | 182 | 208 | 568 | 64 |
| Investments | 5 | 5 | 5 | 4 | 1 | 4 |
| Other Assets | 474 | 490 | 504 | 628 | 572 | 592 |
| Total Assets | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity | 174 | 18 | 69 | 188 | 47 | 175 |
| Cash from Investing Activity | -96 | -32 | -220 | -206 | -307 | -227 |
| Cash from Financing Activity | -79 | 15 | 146 | 22 | 278 | 36 |
| Net Cash Flow | -1 | 1 | -5 | 3 | 19 | -16 |
| Free Cash Flow | 87 | -55 | -155 | -22 | -261 | -50 |
| CFO/OP | 112% | 36% | 124% | 129% | 40% | 99% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 68 | 77 | 72 | 64 | 85 | 83 |
| Inventory Days | 308 | 252 | 305 | 382 | 321 | 274 |
| Days Payable | 155 | 91 | 110 | 259 | 109 | 160 |
| Cash Conversion Cycle | 221 | 238 | 267 | 187 | 298 | 197 |
| Working Capital Days | 86 | 121 | 107 | 76 | -3 | -22 |
| ROCE % | 18% | 6% | 16% | 14% | 13% |
| Sep 2026 | |
|---|---|
| Promoters | 33.28% |
| FIIs | 21.08% |
| DIIs | 27.51% |
| Public | 18.12% |
| No. of Shareholders | 4,27,730 |
Fundamentals
Market Cap₹ 7,345 Cr.
Current Price₹ 1,144
Stock P/E73.8
Book Value₹
ROCE13.0 %
ROE11.7 %
Dividend Yield0.00 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)16%
Compounded Profit Growth (TTM)19%
Consolidated figures.
Valuation
Market capRs 7,691 Cr
Enterprise valueRs 7,745 Cr
P/E (TTM)99.20x
Price to book12.85x
Price to sales11.28x
EV / EBITDA57.61x
EV / EBIT71.31x
EV / sales11.36x
Price to cash flow434.25x
Earnings yield1.01%
Profitability
Operating margin (excl. other income)19.28%
Operating margin (incl. other income)19.72%
EBITDA margin19.72%
Pre-tax margin15.47%
Net profit margin11.37%
ROE13.85%
ROCE17.64%
ROA9.79%
ROIC (approx.)12.19%
Tax rate26.72%
Other income / net worth0.50%
Growth
Sales growth (latest year)7.73%
Profit growth (latest year)-37.11%
Per share
EPS (TTM)Rs 12.08
EPS (latest year)Rs 70.89
Book value per shareRs 93.26
Sales per shareRs 106.21
Cash flow per shareRs 2.76
Free cash flow per shareRs -7.79
Efficiency
Asset turnover0.84x
Fixed asset turnover2.44x
Inventory turnover1.66x
Inventory days220 days
Debtor days77 days
Debtors turnover4.75x
Creditor days160 days
Cash conversion cycle197 days
Working capital days-22 days
Leverage
Total debtRs 65 Cr
Cash and bankRs 11 Cr
Net debtRs 54 Cr
Debt to equity0.11x
Net debt / EBITDA0.40x
Interest coverage34.59x
Owners' fund to total sources73.45%
Debt to assets7.93%
Cash flow
Cash from Operating Activity (latest year)Rs 18 Cr
Cash from Investing Activity (latest year)Rs -32 Cr
Cash from Financing Activity (latest year)Rs 15 Cr
Net Cash Flow (latest year)Rs 1 Cr
Free cash flow (latest year)Rs -50 Cr
FCFE (approx.: FCF + change in debt)Rs -33 Cr
Cash from ops / profit, 5 years1.22x
Sales to cash flow38.50x
Statement figures
Net sales (TTM)Rs 682 Cr
Net sales (latest year)Rs 682 Cr
Operating profit excl. other income (latest year)Rs 131 Cr
Other income (TTM)Rs 3 Cr
EBITDA (TTM)Rs 134 Cr
PBDT (TTM)Rs 131 Cr
Profit before tax (TTM)Rs 105 Cr
Tax (latest year)Rs 28 Cr
Net profit (TTM)Rs 78 Cr
Net profit (latest year)Rs 78 Cr
Depreciation (TTM)Rs 26 Cr
Interest (TTM)Rs 3 Cr
Cost of goods sold (latest year)Rs 407 Cr
Total expenditure (latest year)Rs 550 Cr
Total income (latest year)Rs 685 Cr
Share capitalRs 11 Cr
ReservesRs 588 Cr
Shareholders' fundsRs 599 Cr
Total assetsRs 815 Cr
Net blockRs 280 Cr
Capital work in progressRs 40 Cr
InvestmentsRs 5 Cr
ReceivablesRs 144 Cr
InventoryRs 246 Cr
Other liabilitiesRs 152 Cr
Shares outstanding (crore)6.42
Ownership
Promoter holding33.28%
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | SYMBIOTEC | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +17.0% | -2.8% | +19.8 pts |
| 1 month | +9.1% | -6.8% | +15.9 pts |
58 mutual fund schemes hold about ₹409 Cr.
Over three months 0 bought more and 0 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| ICICI Pru Small Cap Fund | 0.61% | 60 | |
| ICICI Pru Small Cap Fund | 0.61% | 58 | |
| Motilal Oswal Small Cap Fund | 0.59% | 48 | |
| HDFC Pharma and Healthcare Fund | 1.21% | 40 | |
| Mirae Asset Healthcare Fund | 0.98% | 35 | |
| Mahindra Manulife Small Cap Fund | 0.46% | 25 | |
| Edelweiss Large Cap Fund | 1.40% | 20 | |
| Tata Flexi Cap Fund | 0.43% | 16 | |
| Mirae Asset Multi Asset Allocation Fund | 0.29% | 11 | |
| Baroda BNP Paribas Focused Fund | 1.53% | 10 | |
| Tata India Pharma & Healthcare Fund | 0.64% | 10 | |
| Groww Multicap Fund | 0.47% | 7 | |
| WOC Multi Asset Allocation Fund | 0.07% | 6 | |
| Baroda BNP Paribas Health and Wellness Fund | 1.18% | 6 | |
| ICICI Pru Equity Savings Fund(Q | 0.04% | 6 | |
| ITI Flexi Cap Fund | 0.32% | 5 | |
| HDFC MNC Fund | 0.88% | 5 | |
| Edelweiss Recently Listed IPO Fund | 0.41% | 5 | |
| ITI Multi Cap Fund | 0.32% | 5 | |
| TRUSTMF Large & Mid Cap Fund | 1.37% | 5 | |
| TRUSTMF Multi Cap Fund | 0.62% | 5 | |
| Altiva Hybrid Long-Short Fund | 0.04% | 4 | |
| Groww Small Cap Fund | 0.39% | 3 | |
| Mirae Asset Aggressive Hybrid Fund | 0.02% | 2 | |
| Edelweiss Aggressive Hybrid Fund | 0.05% | 2 |
Red flags
F-score 4 of 8| explain | Debt up, profit down Borrowings up 36% while net profit fell in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
No quarterly results published.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
| Date | Type | What it says |
|---|---|---|
| 2026-09-30 | General Updates | Symbiotecs wholly owned subsidiary Knovea Pharmaceutical enters into strategiccommercialization agreement with a leading global pharmaceutical company... |
| 2026-09-30 | General Updates | General Updates |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Symbiotec Pharmalab Ltd?
Symbiotec Pharmalab Ltd (SYMBIOTEC) has a market capitalisation of Rs 7,345 Cr. at the 2026-10-01 close.
What is the P/E ratio of Symbiotec Pharmalab Ltd?
Symbiotec Pharmalab Ltd trades at a P/E of 73.8 on trailing twelve-month profit, at the 2026-10-01 close.
What is the 52-week high and low of Symbiotec Pharmalab Ltd?
The 52-week high is Rs 1,196.80 and the 52-week low is Rs 934.20.